A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene (Q44374802)

2 December 2017

title

A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene (English)

1 reference

2 December 2017

0 references

0 references

David J Drobes

1

1 reference

2 December 2017

Raymond F Anton

series ordinal

2

1 reference

2 December 2017

Suzanne E Thomas

series ordinal

3

1 reference

2 December 2017

Konstantin Voronin

series ordinal

4

1 reference

2 December 2017

language of work or name

English

0 references

publication date

30 October 2002

1 reference

2 December 2017

published in

Neuropsychopharmacology

1 reference

2 December 2017

volume

28

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

755-764

1 reference

The family history method using diagnostic criteria. Reliability and validity

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Effects of naltrexone on alcohol self-administration in heavy drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Naltrexone increases the latency to drink alcohol in social drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Non-specific effect of naltrexone on ethanol consumption in social drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Expectancy and risk for alcoholism: the unfortunate exploitation of a fundamental characteristic of neurobehavioral adaptation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

The Influence of Alternative Reinforcers on Cocaine Use and Abuse: A Brief Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Hepatic and metabolic effects of ethanol: pathogenesis and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Sensitivity of nicotine-containing and de-nicotinized cigarette consumption to alternative non-drug reinforcement: a behavioral economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Naltrexone-induced alterations in human ethanol intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

An inventory for measuring clinical anxiety: psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Discriminant analysis of the Self-Administered Alcoholism Screening Test

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Naltrexone in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Alcohol dependence syndrome: measurement and validation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Compliance among heavy alcohol users in clinical drug trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Naltrexone and alcohol dependence. Role of subject compliance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300101

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300101

1 reference

2 December 2017

1 reference